Cargando…
PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening.
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616811/ http://dx.doi.org/10.1093/ijnp/pyw043.216 |
| _version_ | 1783266870437085184 |
|---|---|
| author | Allers, Kelly Alastalo, S Bretschneider, Tom Hengerer, Bastian Hoke, J Kleiner, Oliver Kontakanen, O Liesener, Andre Nold, Verena Nurmi, A Otto, Markus Pleiner, S Puolivali, J Schoenfeldt, Carlos Stierstorfer, Birgit |
| author_facet | Allers, Kelly Alastalo, S Bretschneider, Tom Hengerer, Bastian Hoke, J Kleiner, Oliver Kontakanen, O Liesener, Andre Nold, Verena Nurmi, A Otto, Markus Pleiner, S Puolivali, J Schoenfeldt, Carlos Stierstorfer, Birgit |
| author_sort | Allers, Kelly |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5616811 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56168112017-11-27 PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. Allers, Kelly Alastalo, S Bretschneider, Tom Hengerer, Bastian Hoke, J Kleiner, Oliver Kontakanen, O Liesener, Andre Nold, Verena Nurmi, A Otto, Markus Pleiner, S Puolivali, J Schoenfeldt, Carlos Stierstorfer, Birgit Int J Neuropsychopharmacol Abstracts Oxford University Press 2016-05-27 /pmc/articles/PMC5616811/ http://dx.doi.org/10.1093/ijnp/pyw043.216 Text en © The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. |
| spellingShingle | Abstracts Allers, Kelly Alastalo, S Bretschneider, Tom Hengerer, Bastian Hoke, J Kleiner, Oliver Kontakanen, O Liesener, Andre Nold, Verena Nurmi, A Otto, Markus Pleiner, S Puolivali, J Schoenfeldt, Carlos Stierstorfer, Birgit PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. |
| title | PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. |
| title_full | PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. |
| title_fullStr | PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. |
| title_full_unstemmed | PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. |
| title_short | PS216. Preclinical and clinical assessment of tryptophan catabolites (TRYCATS) as a measure of neuroinflammation and utility in compound screening. |
| title_sort | ps216. preclinical and clinical assessment of tryptophan catabolites (trycats) as a measure of neuroinflammation and utility in compound screening. |
| topic | Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616811/ http://dx.doi.org/10.1093/ijnp/pyw043.216 |
| work_keys_str_mv | AT allerskelly ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT alastalos ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT bretschneidertom ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT hengererbastian ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT hokej ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT kleineroliver ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT kontakaneno ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT liesenerandre ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT noldverena ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT nurmia ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT ottomarkus ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT pleiners ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT puolivalij ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT schoenfeldtcarlos ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening AT stierstorferbirgit ps216preclinicalandclinicalassessmentoftryptophancatabolitestrycatsasameasureofneuroinflammationandutilityincompoundscreening |